AcuCort AB announces that the trademark for the company’s drug Zeqmelit® has been registered for trademark protection in India.
The trademark protection is of strategic importance as the company enters the commercialization phase.
"It is very gratifying that we have now obtained trademark protection in India for our oral film Zeqmelit® and its associated applications. This is an important step towards commercialization in India," says Jonas Jönmark”, CEO of AcuCort.
The trademark protection for Zeqmelit® in India is valid for the next 10 years, after which the company must apply for an extension.
Zeqmelit® is also trademarked in Europe (all European Union member states), Norway, Switzerland, the USA, the UK, Australia, China, and Japan.
Trademark protection is issued by the International Bureau of the World Intellectual Property Organization (WIPO).
For further information:
Jonas Jönmark, CEO AcuCort AB
Tel: +46 70 3655400
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se for more information.